Skip to main content

Table 5 Effectiveness of LCN2, CD24, and Lactoferrin as a predictor set for discriminating between the control and SU5416 treatment arms.*

From: Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

1. All cases pooled (67 cases from both trials)
  Trial arm Predicted trial arm
   Control SU5416 % Correct
  Control 26 5 84
  SU5416 6 30 83
  Total 32 35 84
2. Jackknifed classification matrix for all cases pooled (67 cases from both trials)
   Control SU5416 % Correct
  Control 26 5 84
  SU5416 8 28 78
  Total 34 33 81
3. Prediction subset (randomly selected 34 cases) from all cases pooled
   Control SU5416 % Correct
  Control 13 1 93
  SU5416 4 16 80
  Total 17 17 85
4. Validation subset (randomly selected 33 cases) from all cases pooled
   Control SU5416 % Correct
  Control 11 6 65
  SU5416 5 11 69
  Total 16 17 67
  1. *Cross-validation results are displayed for two different approaches. In section 2, one case is dropped at a time and its group membership predicted from the other cases. In sections 3 and 4, cross-validation is carried out by using a randomly selected half of the cases as a training set and the remaining half as a test set. Section 4 summarizes the prediction accuracy achieved when the group in section 3 is used as a training set. Note: When results of one trial were used in predictive classification of results from the other trial, the accuracy in cross-validation was 86% and 77% for the training and testing set, respectively (with a Cohen's kappa value of 0.5507).